Oryon Cell Therapies
Updated: March 24, 2026
CEO - Ron Cohen
Country: USA | Funding: $21M (+)
Founded: 2020
Website: https://oryoncelltherapies.com
Oryon develops cell therapies for Parkinson's disease by targeting dopamine production. Most current treatments rely on neuronal progenitor cells, which are implanted into the brain, where they proliferate and eventually become A9 neurons - the primary dopamine-producing cells that degenerate in Parkinson's patients, causing the disease's motor symptoms. In contrast, Oryon implants fully developed A9 neurons from the start, aiming to more directly restore dopamine production. Another key difference is its unilateral approach: the company treats only one side of the brain, while most competing programs utilize bilateral treatment. The company's lead program is in clinical trials and has shown improvement in motor function, as well as neuroimaging data indicating restoration of dopaminergic signaling in the transplanted brain region.
Founded: 2020
Website: https://oryoncelltherapies.com
Oryon develops cell therapies for Parkinson's disease by targeting dopamine production. Most current treatments rely on neuronal progenitor cells, which are implanted into the brain, where they proliferate and eventually become A9 neurons - the primary dopamine-producing cells that degenerate in Parkinson's patients, causing the disease's motor symptoms. In contrast, Oryon implants fully developed A9 neurons from the start, aiming to more directly restore dopamine production. Another key difference is its unilateral approach: the company treats only one side of the brain, while most competing programs utilize bilateral treatment. The company's lead program is in clinical trials and has shown improvement in motor function, as well as neuroimaging data indicating restoration of dopaminergic signaling in the transplanted brain region.
